A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss
Harvey J. Sugerman, Florence F. Vickers, Jeffrey C. Oram-Smith(University of Colorado Colorado Springs), Dapo Popoola, Louis F. Martin(Pennsylvania State University), Bruce D. Schirmer(University of Virginia), Alex M. C. Macgregor, Kenneth G. MacDonald(East Carolina University), Mathias Fobi, Robert E. Brolin(Rutgers, The State University of New Jersey), Mitchell L. Shiffman(Bon Secours Health System), John H. Linner, William H. Brewer(Virginia Commonwealth University Medical Center)
Cited by 401
Related Papers
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k
Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations
|Diabetes Care|2016|969
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877